


January 15, 1992



Cancer Research

OFFICIAL JOURNAL OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH

VOLUME 52 • NO. 2 • PP 249-499

ISSN 0008-5472 • CNREA 8

The Second Joint
Meeting of the American
Association for Cancer
Research and the
Japanese Cancer
Association

Molecular Oncology as a Basis for New Strategies in Cancer Therapy



癌

Honolulu, Hawaii
February 10-14, 1992

Antibodies For Cancer Research

Antibody reagents for the identification of proteins in the study of cancer.

- *c-erbB-2* Oncogene Antibodies
- HPV-16 E7 Monoclonal Antibody
- Retinoblastoma (RB) Gene Product Monoclonal Antibody
- TAG-72 Monoclonal Antibody (B72.3)



1401 Harbor Bay Parkway, Alameda, CA 94501
1-800-874-8667 • 1-800-682-6200 (CA only)
TEL: 1-510-769-5202 • FAX: 1-510-769-5252

FOR RESEARCH USE ONLY. Not for use in diagnostic procedures.

CANCER CENTER DIRECTOR

The University of Florida College of Medicine is seeking a Cancer Center Director which will hold a 12 month academic administrative appointment and reports to the Dean of the College of Medicine. This individual will hold a tenure track faculty appointment as Professor. The candidate should have an M.D. Degree with excellent clinical credentials and a solid track record in research achievement.

Responsibilities include: The Cancer Center Director will serve as the Medical Director of the ambulatory Cancer Center and will serve as Director of the Cancer Center. The Director will promote multidisciplinary clinical and research activities in areas related to cancer. The Director will direct activities in support of the institution's application for the Cancer Center core grant; will recruit research faculty to endowed chairs related to cancer research. The Director will develop cancer screening and community education projects as appropriate. The Director will serve as chairperson of the Cancer Center Steering Committee and administer space assignments for the Cancer Center.

Letters of application should consist of a current vitae and include a summary of relevant research, clinical and administrative experience. The application deadline is 03/15/92. Applications should be sent to:

James E. McGuigan, M.D., Search Committee Chairman
Chairman, Department of Medicine
University of Florida College of Medicine
Box 100277
Gainesville, FL 32610-0277

The University of Florida is an Equal Employment
Opportunity/Affirmative Action Employer.

MEDICAL ONCOLOGIST ASSISTANT/ASSOCIATE PROFESSOR

Roswell Park Cancer Institute

Applications are being accepted for the positions of Assistant/Associate Professor of Medicine in Roswell Park Cancer Institute's Divisions of Solid Tumor Oncology and Investigational Therapeutics. The incumbent's responsibilities include the provision of consultative and attending services in Medical Oncology, teaching students and supervision of residents and fellows. Assistant Professor candidates must show evidence of experience in clinical care and teaching, and demonstrate potential to develop an outstanding clinical or laboratory research program in Solid Tumor Oncology. Associate Professor candidates must provide evidence of a strong research program as well as demonstrate skill in clinical care and teaching. Candidates must be Board Certified in Internal Medicine and Board Eligible or Certified in Medical Oncology, as well as be able to meet Medical Licensure requirements in New York State. Send Curriculum Vitae to:

Clara D. Bloomfield, M.D.
Head, Department of Medicine

OR


Derek Raghavan, M.D., Ph.D.
Chief, Solid Tumor Oncology and
Investigational Therapeutics

Department of Medicine
Roswell Park Cancer Institute
Elm and Carlton Streets, Buffalo, NY 14263



Roswell Park is an Equal Opportunity/Affirmative Action Employer.

COVER LEGEND



The Second Joint Meeting of the American Association for Cancer Research and the Japanese Cancer Association (JCA) will be held in Hawaii from February 10 to 14, 1992, at the Sheraton Waikiki Hotel, Honolulu. With the title, "Molecular Oncology as a Basis for New Strategies in Cancer Therapy," the five-day program will embrace sessions devoted to new

developments in the following areas: Oncogenes and Tumor Suppressor Genes; Growth Factors, Cytokines, and Receptors; The Cell Surface, Signal Transduction and Chemoprevention; Recent Advances in Chemotherapy and Drug Resistance; Molecular Targeting Approaches; and Molecular Genetics, Models, and Strategies. The conference will open with keynote addresses by Takashi Sugimura, "Multiple Primary Cancers in Humans and Their Relevance to Cancer Therapy," and Bruce Chabner, "Recent Advances in Experimental Chemotherapy and Clinical Trials." An overview and summary will be provided by Yung-chi Cheng at the end of the conference. Co-Chairpersons of the Program Committee are I. Bernard Weinstein of the Columbia University Comprehensive Cancer Center and Susumu Nishimura of the National Cancer Center Research Institute.

Highlighted are recent advances in the molecular biology of cancer and biotechnology as applied to new strategies for therapy. In addition to an outstanding list of invited speakers, over 200 proffered poster presentations will be given.

This second joint conference, which is a manifestation of the continuing close collaboration between the AACR and the JCA, has engendered a great deal of early interest. Future joint meetings with the Japanese cancer research community will also be held in Hawaii.

Sidney Weinhouse